1Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
2Department of Neurology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea
3Department of Neurology, Ewha Womans University School of Medicine, Ewha Womans University Mokdong Hospital, Seoul, Korea
4Department of Neurology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
5Department of Neurology, Nowon Eulji Medical Center, Eulji University, Seoul, Korea
6Department of Neurology, Kyung Hee University Medical Center, Seoul, Korea
7Department of Neurology, Seoul Central Clinic, Seoul, Korea
8Department of Neurology, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Korea
9Department of Neurology, Seoul St. Mary’s Hospital, Catholic University of Korea, Seoul, Korea
10Department of Neurology, Presbyterian Medical Center, Jeonju, Korea
Copyright © 2018 The Korean Movement Disorder Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of Interest
B Jeon received a research grant from Kunil Pharmaceuticals, Peptron, Novartis Korea, Ipsen Korea, Samil Pharmaceuticals, Abbvie Korea, and Lundbeck Korea. He is a medical advisor to Bukwang Pharmaceuticals.
All patients (n = 56) | A-1 (n = 19) | A-2 (n = 19) | B (n = 18) | p value | |
---|---|---|---|---|---|
Men | 26 (46.4) | 11 (57.9) | 6 (31.6) | 9 (50.0) | 0.249 |
Age (yr) | 55.27 ± 8.69 | 54.95 ± 6.52 | 55.68 ± 9.22 | 55.17 ± 10.44 | 0.978 |
Age of onset (yr) | 53.57 ± 9.41 | 53.32 ± 6.94 | 54.00 ± 9.76 | 53.39 ± 11.58 | 0.985 |
PD duration (yr) | 1.71 ± 1.96 | 1.63 ± 1.83 | 1.68 ± 1.77 | 1.83 ± 2.36 | 0.955 |
H&Y | 1.63 ± 0.54 | 1.47 ± 0.51 | 1.63 ± 0.50 | 1.81 ± 0.57 | 0.175 |
UPDRS I | 1.48 ± 1.72 | 1.69 ± 1.67 | 1.33 ± 2.06 | 1.41 ± 1.42 | 0.521 |
UPDRS II | 5.17 ± 4.00 | 5.44 ± 4.59 | 5.17 ± 4.60 | 4.88 ± 2.64 | 0.920 |
UPDRS III | 19.29 ± 8.01 | 19.62 ± 9.12 | 17.85 ± 6.37 | 20.70 ± 8.70 | 0.727 |
Tremor-dominant subtype* | 27 (54.0) | 9 (52.9) | 11 (55.0) | 7 (50.0) | 0.982 |
MMSE | 27.10 ± 4.60 | 27.36 ± 1.91 | 25.93 ± 7.66 | 28.00 ± 1.56 | 0.744 |
FAB | 15.71 ± 2.64 | 16.14 ± 1.23 | 15.00 ± 4.11 | 16.00 ± 1.62 | 0.959 |
Data are expressed as n (%) or mean ± standard deviation.
* calculations of the percentage of patients with the tremor-dominant subtype and the chi-squared test were performed after excluding 6 patients with incomplete evaluations. PD: Parkinson’s disease, H&Y: Hoehn and Yahr stage, UPDRS: Unified Parkinson’s Disease Rating Scale, MMSE: Mini-Mental Status Examination, FAB: Frontal Assessment Battery.
Comments on this article